文献速递肾小球疾病

国际肾脏病学会论坛:补体治疗在C3肾小球病与IgA肾病中的结局

Outcomes from the International Society of Nephrology forum on complement therapeutics in C3 glomerulopathy and IgA nephropathy.
PubMed 文献 · Kidney Int · 2026-08-26

2025年国际肾脏病学会论坛汇集全球专家,讨论补体治疗在C3肾小球病(C3G)、免疫复合物膜增生性肾小球肾炎(IC-MPGN)和IgA肾病(IgAN)中的当前知识与不确定性。C3G和IC-MPGN中补体过度激活是原发驱动因素,而IgAN中补体为继发因素。近期临床试验成功应用替代途径补体抑制剂,但真实世界应用策略尚待明确。

要点

  • C3G和IC-MPGN中补体过度激活是疾病原发驱动因素。
  • IgAN中补体为继发因素,参与肾脏损伤。
  • 替代途径补体抑制剂临床试验成功,但真实世界应用策略待明确。

核心结论

  • C3G和IC-MPGN是补体过度激活驱动的原型疾病,IgAN中补体为继发因素。
  • 替代途径补体抑制剂在C3G、IC-MPGN和IgAN中临床试验成功,但真实世界应用策略需进一步明确。

研究设计与样本

  • 2025年国际肾脏病学会论坛,全球专家小组评估当前知识、识别不确定性并提出解决方案。

主要发现

  • 补体生物标志物、补体自身抗体、遗传学和肾脏活检如何指导治疗尚不确定。
  • 论坛讨论了补体抑制剂的使用理由及其在当前治疗格局中的地位。

临床怎么用

  • 补体抑制剂可用于C3G、IC-MPGN和IgAN,但需根据补体生物标志物、自身抗体、遗传学和肾活检指导治疗。

局限性

  • 补体生物标志物、自身抗体、遗传学和肾活检指导治疗的不确定性领域需未来研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) are both prototypical complement disorders in which complement overactivation is the primary driver of disease. Complement is not the primary cause of disease in IgA nephropathy (IgAN); however, increasing evidence implicates complement as a secondary factor in kidney damage in this more complex, multifactorial disorder. The success of recent clinical trials using alternative pathway complement inhibitors in C3G, IC-MPGN, and IgAN pose questions as to how they should be used in the real world. We report the findings of the 2025 International Society of Nephrology Forum on Complement Therapeutics in C3G and IgAN, where a global panel of experts considered the current state of knowledge, identified areas of uncertainty, and proposed optimal solutions. Areas of uncertainty and areas for future research included how complement biomarkers, complement autoantibodies, genetics, and the kidney biopsy guide therapy. The current rationale for the use of complement inhibitors and their place within the current therapeutic landscape are discussed.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Kavanagh D, Alladin-Karan A, Alexander S, et al. Outcomes from the International Society of Nephrology forum on complement therapeutics in C3 glomerulopathy and IgA nephropathy. Kidney Int. 2026. PMID: 42648401. doi:10.1016/j.kint.2026.08.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。